TABLE 1.
Clinical characteristics of COVID‐19 patients at hospital admission
| Overall population (n 97) | |
|---|---|
| Sex, m (%) | 68 (70%) |
| Age, years, mean ± SD | 61 ± 13 |
| Obesity, n (%) | 22 (23%) |
| BMI, kg/m2, mean ± SD | 28 ± 4 |
| COPD, n (%) | 7 (8%) |
| Diabetes, n (%) | 14 (14%) |
| Hypertension, n (%) | 40 (41%) |
| Coronary artery disease, n (%) | 12 (12.4%) |
| Peripheral vasculopathy, n (%) | 11 (11.3%) |
| Heart failure, n (%) | 4 (4.1%) |
| Renal failure, n (%) | 9 (15%) |
| ΔA‐aO2, mm Hg, median (Q1‐Q3) | 204 (138‐240) |
| PaO2/FiO2, mm Hg, median (Q1‐Q3) | 221 (172‐283) |
| Systolic BP, mm Hg, mean ±SD | 133 ± 18 |
| Diastolic BP, mm Hg, mean ±SD | 77 ± 11 |
| Mean BP, mm Hg, mean ±SD | 96 ± 12 |
| WBC, ×103/µL, median (Q1‐Q3) | 7.34 (5.33‐9.85) |
| Neutrophils, ×103/µL, median (Q1‐Q3) | 5.84 (3.79‐8.09) |
| Lymphocytes, ×103/µL, median (Q1‐Q3) | 0.83 (0.63‐1.22) |
| Monocytes, ×103/µL, median (Q1‐Q3) | 0.41 (0.27‐0.60) |
| Eosinophil, ×103/µL, median (Q1‐Q3) | 0.01 (0.00‐0.06) |
| Basophil, ×103/µL, median (Q1‐Q3) | 0.01 (0.01‐0.02) |
| CRP, mg/dL, mean ± SD | 11 ± 8 |
| D‐dimer, µg/L, median (Q1‐Q3) | 1270 (682‐1977) |
| LDH, U/L, median (Q1‐Q3) | 311 (250‐424) |
| Ferritin, mg/L, median (Q1‐Q3) | 1111 (514‐2478) |
| NT‐proBNP, ng/L, median (Q1‐Q3) | 271 (75‐893) |
| Tn‐T, ng/L, median (Q1‐Q3) | 12 (6‐23) |
| IL‐6, ng/L, median (Q1‐Q3) | 40 (12‐97) |
| Triglycerides, mg/dL, median (Q1‐Q3) | 151 (123‐193) |
| Total cholesterol, mg/dL, median (Q1‐Q3) | 134 (107‐171) |
| HDL‐C, mg/dL, mean ± SD | 28 ± 10 |
| Non‐HDL‐C, mg/dL, median (Q1‐Q3) | 109 (85‐137) |
| PCSK9, ng/mL, median (Q1‐Q3) | 339 (251‐430) |
| Apolipoprotein B, g/L, mean ± SD | 0.7 ± 0.5 |
| Lipoprotein(a), nmol/L, median (Q1‐Q3) | 21 (11‐44) |
| ACE2, ng/mL, median (Q1‐Q3) | 68.2 (48‐91) |
| Lopinavir/ritonavir, n (%) | 97 (100%) |
| Hydroxychloroquine, n (%) | 97 (100%) |
| Low‐molecular‐weight heparin (LMWH), n (%) | 97 (100%) |
| Methylprednisolon, n (%) | 34 (35%) |
| Tocilizumab, n(%) | 3 (3%) |
| Disease duration, days, median (Q1‐Q3) | 12 (8‐19) |
| Overall mortality, %, (n. of deaths) | 20.6% (20) |
Data are expressed as mean ± SD (standard deviation) or median (first (Q1) and third (Q3) quartiles).
Abbreviations: ACE2, angiotensin‐converting enzyme 2; BMI, body mass index; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; HDL‐C, high‐density lipoprotein cholesterol; IL‐6, interleukin 6; LDH, lactate dehydrogenase; NT‐proBNP, N‐terminal pro–brain natriuretic peptide; PaO2/FiO2, pressure of arterial oxygen to fractional inspired oxygen concentration; PCSK9, proprotein convertase subtilisin/kexin type 9; Tn‐T, troponin T; WBC, white blood cells; ΔA‐aO2, alveolar‐arterial oxygen gradient (ΔA‐aO2).